Diabetic Neuropathy of the Retina and Inflammation: Perspectives

Bikbova, Guzel; Oshitari, Toshiyuki; Бикбов, М.М.

doi:10.3390/ijms24119166

Cited by 5 publications

(3 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest percentage of patients with diabetic neuropathy was in the Cluster 2 which also had the pronounced levels of NLR and PLR but significantly lower than in the Cluster 3. This could be explained by multifactorial nature of the retinopathy and neuropathy where inflammation is just one aspect of a broader pathophysiological picture 32 .…”

Section: Discussionmentioning

confidence: 99%

Cluster analysis of patient characteristics, treatment modalities, renal impairments, and inflammatory markers in diabetes mellitus

Cojic,

Klisic,

Sahmanovic

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is caused by an interplay of various factors where chronic hyperglycemia and inflammation have central role in its onset and progression. Identifying patient groups with increased inflammation in order to provide more personalized approach has become crucial. We hypothesized that grouping patients into clusters according to their clinical characteristics could identify distinct unique profiles that were previously invisible to the clinical eye. A cross-sectional record-based study was performed at the Primary Health Care Center Podgorica, Montenegro, on 424 T2DM patients aged between 30 and 85. Using hierarchical clustering patients were grouped into four distinct clusters based on 12 clinical variables, including glycemic and other relevant metabolic indicators. Inflammation was assessed through neutrophil-to-lymphocyte (NLR) and platelet to lymphocyte ratio (PLR). Cluster 3 which featured the oldest patients with the longest T2DM duration, highest hypertension rate, poor glycemic control and significant GFR impairment had the highest levels of inflammatory markers. Cluster 4 which featured the youngest patients, with the best glycemic control, the highest GFR had the lowest prevalence of coronary disease, but not the lowest levels of inflammatory markers. Identifying these clusters offers physicians opportunity for more personalized T2DM management, potentially mitigating its associated complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Cluster analysis of patient characteristics, treatment modalities, renal impairments, and inflammatory markers in diabetes mellitus

Cojic,

Klisic,

Sahmanovic

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In patients with DM, the metabolism of glucose, lipids, proteins, and nuclear acids is largely dysregulated. Under hyperglycemia, lipids, proteins, and nuclear acids can form advanced glycation end products, interact with the corresponding receptor and finally trigger the activation of inflammation, oxidative stress, and mitochondrial dysfunction, which ultimately induces neuronal injury (43)(44)(45)(46).…”

Section: Preclinical Evidence Of Neuroprotective Effects Of Glp-1r Ag...mentioning

confidence: 99%

Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy

Liu,

Wu,

Ren

2024

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetes mellitus is a prevalent chronic disease characterized by hyperglycemia. Diabetic peripheral neuropathy (DPN) is one of the complications of diabetes mellitus and is caused by neuron injury induced by hyperglycemic circumstances. The incidence of DPN varies among different countries and regions, ranging from nearly 20% to over 70%. Patients with DPN may encounter symmetric pain or discomfort of the extremes, leading to reduced quality of life and even amputation. The pharmacological management for painful DPN mainly includes antidepressants due to their analgesic effects. Nevertheless, effective therapies to impact the pathogenesis and progression of DPN are lacking. Glucagon-like peptide-1 receptor (GLP-1R) agonists show efficacy in controlling blood glucose and serve as a treatment modality for diabetes mellitus. In recent years, evidence has been proposed that GLP-1R agonists exert neuroprotective effects through modulating inflammation, oxidative stress, and mitochondrial dysfunction. On the other hand, clinical evidence on the potential of GLP-1R agonists for treating DPN is still controversial and limited. This narrative review summarizes the preclinical and clinical studies investigating the capacity of GLP-1R agonists as therapeutic agents for DPN.

show abstract

“…The Nomenclature Committee on Cell Death (NCCD) defines pyroptosis as RCD accompanied by the formation of plasma membrane pores by the gasdermin protein family, which is often induced by inflammatory caspase activation [ 57 ]. Diabetes mellitus is a chronic inflammatory disease; thus, pyroptosis, an inflammation-related RCD, is associated with the pathogenesis of diabetes mellitus and DR [ 58 , 59 ]. A hypothetical mechanism of pyroptosis is shown in Figure 2 .…”

Section: Various Types Of Retinal Cell Death In Drmentioning

confidence: 99%

Neurovascular Cell Death and Therapeutic Strategies for Diabetic Retinopathy

Oshitari

2023

IJMS

Self Cite

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is a major complication of diabetes and a leading cause of blindness worldwide. DR was recently defined as a neurovascular disease associated with tissue-specific neurovascular impairment of the retina in patients with diabetes. Neurovascular cell death is the main cause of neurovascular impairment in DR. Thus, neurovascular cell protection is a potential therapy for preventing the progression of DR. Growing evidence indicates that a variety of cell death pathways, such as apoptosis, necroptosis, ferroptosis, and pyroptosis, are associated with neurovascular cell death in DR. These forms of regulated cell death may serve as therapeutic targets for ameliorating the pathogenesis of DR. This review focuses on these cell death mechanisms and describes potential therapies for the treatment of DR that protect against neurovascular cell death.

show abstract

Diabetic Neuropathy of the Retina and Inflammation: Perspectives

Cited by 5 publications

References 128 publications

Cluster analysis of patient characteristics, treatment modalities, renal impairments, and inflammatory markers in diabetes mellitus

Cluster analysis of patient characteristics, treatment modalities, renal impairments, and inflammatory markers in diabetes mellitus

Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy

Neurovascular Cell Death and Therapeutic Strategies for Diabetic Retinopathy

Contact Info

Product

Resources

About